

CORPORATE NEWS

MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de

MeVis' profitability remains high with stable revenues

Sales increase of 9 % in the second quarter offsets decline in sales from the previous quarter

- Consolidated sales after the first six month with € 6.9 million stabilized on the level of the previous year
- Maintenance business contributes 44 % to the revenues (prev. year: 43 %)
- Earnings before interest and taxes (EBIT) again significantly increased by 30 % to € 1.6 million (prev. year: € 1.3 million)
- Consolidated net profit also increased considerably to € 1.6 million (prev. year: € 0.7 million)
- Liquidity raised to € 9.6 million (December 31, 2012: € 8.7 million)

Bremen, August 26, 2013 – Today, MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software provider for the medical imaging market, announced its results for the first half of 2013.

Sales in the second quarter of 2013 exceeded the prior-year quarter with € 3,544 k, by 9 % (€ 3,241 k). At € 6,862 k, sales in the first half of the year were constant year on year (prev. year: € 6,878 k). Maintenance and service revenues again rose by 2 % to € 3,036 k (prev. year: € 2,978 k) and contributed 44 % of total revenue (prev. year: 43 %). In contrast, license sales declined slightly by 4 % to € 3,520 k (prev. year: € 3,670 k)

Group sales in the second quarter up by 9 % year on year, maintenance business grows slightly

Sales in the Digital Mammography segment went up slightly by 1 % to € 5,186 k (prev. year: € 5,145 k). In contrast, sales in the Other Diagnostics segment declined by 3 % to € 1,676 k (prev. year: € 1,733 k).

Capitalized development expenses were significantly reduced by 46 % in the first half of 2013 year on year to € 760 k (prev. year: € 1,409 k).

Operating costs were again significantly reduced in the second quarter of 2013. Personnel expenses amounted to € 1,927 k, 9 % down on the prior-year quarter. For the first half of the year, this corresponds to a total drop of 12 %. Other

Successful cost management further increases operating profitability

operating expenses also decreased to € 434 k, corresponding to a 21 % drop year on year.

After depreciation and amortization of € 1,033 k (38 % down year on year) the first half of 2013 results in an EBIT (earnings before interest and taxes) of € 1,638 k, up a significant 30 % on the prior-year figure of € 1,256 k, mainly due to a consistent cost management. The EBIT margin increased to 24 % (prev. year: 18 %).

EBIT substantially stronger than previous year, margin now 24 %

With a net financial result of € -82 k and very low income tax the first half of 2013 closed on a very positive note, with consolidated net profit of € 1,551 k (prev. year: € 666 k). This resulted in earnings per share of € 0.90 (prev. year: € 0.39).

Consolidated net profit increased from € 0.7 million to € 1.6 million

Cash and cash equivalents went up in the first half of 2013 by € 902 k to € 9,568 k (€ 8,665 k as of December 31, 2012).

Group liquidity rose to € 9.6 million

"Based on our current performance we are raising our forecast for 2013. We now expect a stable growth in sales instead of a slight decline in sales. In our assessment the Group's earnings before interest and taxes (EBIT) are substantially influenced by the sales performance, by a reduced capitalization of development costs and by a further slight reduction in personnel expenses and other operating expenses. Overall for 2013, we now expect an increase in EBIT instead of a slight decline. Further, we expect a positive cash flow for this year." said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. „We are also pleased that we have largely completed the streamlining of the Group structure with the merger of MeVis BreastCare Solutions (MBS) with its parent company MMS AG, which came into effect on August 1."

Forecast for 2013 raised

Merger of MBS with MMS AG effective August 1

"Now that the consolidation measures have largely been concluded with corresponding positive effects on our results we have laid a solid foundation for MeVis' future growth." added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. "We will continue to focus on the development and implementation of measures to generate future sales growth. We have also continued our promising talks with potential new industrial customers to gain additional customers in our core business of selling software licenses and therefore to modify and expand our product portfolio to meet the needs of our customers. In order to build up the business with internet-based services, we will launch initial services on the market in the fourth quarter of this year and gradually expand these services."

Growth with existing and new industrial customers as well as new distribution channels

The financial reports of the company can be downloaded here:

http://www.mevis.de/ir_finanzberichte.html

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.